Percheron L, et al. - Researches performed a retrospective analysis on behalf of the French Society of Pediatric Nephrology, wherein they assessed if treatment with eculizumab (EC), a monoclonal antibody against terminal complement complex, for severe hemolytic uremic syndrome related to Shiga-toxin-secreting Escherichia coli infection (STEC-HUS) yielded favorable outcomes. They examined 33 children from 15 centers treated with EC for STEC-HUS, with the indication for EC being neurologic involvement in 20 patients, cardiac and neurologic involvement in 8, cardiac involvement in 2, and digestive involvement in 3. Based on the findings, treatment with EC in severe STEC-HUS patients, specifically those presenting severe neurological symptoms, may be supported.